Search clinical trials for: OSI-211 (Liposomal Lurtotecan)

Total 106 results

Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer

SCLC | Carcinoma, Small Cell

United Kingdom, United States
Astellas Pharma Inc
OSI Pharmaceuticals

Completed

Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer

Ovarian Neoplasms

United Kingdom, United States
European Organisation for Research and Treatment...

Completed

Liposomal Lurtotecan in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer

Head and Neck Cancer

France, Spain, Switzerland, Belgium, Netherlands, Portugal, United Kingdom, Italy, Germany, Austria
NCIC Clinical Trials Group

Completed

Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

Canada, United Kingdom
NCIC Clinical Trials Group

Completed

Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors

Head and Neck Cancer | Ovarian Cancer | Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific

Canada
NCIC Clinical Trials Group
Nexstar Pharmaceuticals

Completed

Lurtotecan Liposome in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

Canada
Sanofi

Completed

A Study Evaluating BSI-201 in Combination With Chemotherapeutic Regimens in Subjects With Advanced Solid Tumors

Tumors

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma

Intraocular Retinoblastoma

United States, Canada, Australia, New Zealand, India
Maria Sklodowska-Curie National Research Institute...

Recruiting

Phase 1b/2 Study of Liposomal Annamycin (L-Annamycin) in Subjects With Previously Treated Soft-Tissue Sarcomas (STS) With Pulmonary Metastases (ANNA-SARC)

Soft Tissue Sarcoma | Pulmonary Metastasis

Poland
Sanofi

Completed

A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors

Neoplasm Malignant

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma

Intraocular Retinoblastoma

United States
Sanofi

Completed

Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Primary Peritoneal Cancer | Advanced Epithelial Ovarian Cancer

United States
Sanofi

Completed

Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

Solid Tumors

Belgium, Italy, United States, Spain
National Institutes of Health Clinical Center (CC)
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia

Adrenal Insufficiency | Congenital Adrenal Hyperplasia (CAH) | Excess Androgen

United States
Sanofi

Completed

An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi)

Advanced Solid Tumors

United States
Sanofi

No longer available

An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer

Breast Cancer
Institut du Cancer de Montpellier - Val d'Aurelle

Terminated

A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases (RAPIBE)

Brain Metastases

France
Sanofi

Completed

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer

Ovarian Cancer

United States
Sanofi

Completed

A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Ovarian Cancer

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian... and other conditions

United States, Puerto Rico
Sanofi

Completed

Study of the Poly (ADP-ribose) Polymerase-1 (PARP-1) Inhibitor BSI-201 in Patients With Newly Diagnosed Malignant Glioma

Glioblastoma

United States
National Cancer Institute (NCI)

Withdrawn

A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma
Sanofi

Completed

Phase 1/1b Dose Escalation Study Evaluating BSI-201 as a Single Agent and in Combination With Irinotecan in Subjects With Advanced Solid Tumors

Tumors

United States
Jonsson Comprehensive Cancer Center
Jazz Pharmaceuticals

Active, not recruiting

CPX-351 Plus Enasidenib for Relapsed AML

Recurrent Acute Myeloid Leukemia

United States
OnKure, Inc.

Recruiting

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer (PIKture-01)

Breast Cancer | Advanced Cancer

United States
Spectrum Pharmaceuticals, Inc

Terminated

A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects ≥ 60 Years Old With Newly Diagnosed ALL

Acute Lymphoblastic Leukemia (ALL)

United States
Sanofi
SOLTI Breast Cancer Research Group

Completed

Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients (SOLTI NEOPARP)

Breast Cancer Female

Spain, France, Germany
BBB-Therapeutics B.V.

Terminated

Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients

Multiple Sclerosis | Healthy Volunteers

Netherlands
Sanofi
Gynecologic Oncology Group

Completed

Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma

Uterine Carcinosarcoma

United States
Sanofi
Breast Cancer Research Foundation

Completed

A Phase 2 Study of Standard Chemotherapy Plus BSI-201 (a PARP Inhibitor) in the Neoadjuvant Treatment of Triple Negative Breast Cancer

Triple Negative Breast Cancer

United States
Sanofi

Completed

SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Stage IV

Spain, France, Germany, Italy, United Kingdom
Sanofi

Completed

Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid Tumors

Advance Solid Tumors

Japan
Sanofi

Completed

Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer

Breast Cancer, Metastatic

Australia, Belgium, France, Italy, Netherlands, Spain
Sanofi
BiPar Sciences

Completed

A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer

Breast Cancer

United States
Sanofi

Completed

A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer

Breast Cancer

United States
Mayo Clinic

Recruiting

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Human Papillomavirus-Related Carcinoma | Locally Advanced Oropharyngeal Carcinoma

United States
National Cancer Institute (NCI)

Terminated

Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer

Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Adenocarcinoma of the Lung | Bronchoalveolar Cell Lung Cancer | Large Cell Lung Cancer

United States
Garden State Cancer Center at the Center for Molecular...

Completed

Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer

Head and Neck Cancer

United States
Genprex, Inc.

Terminated

TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer

Lung Cancer

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)

Recurrent Childhood Acute Lymphoblastic Leukemia

United States, Australia, Canada, Puerto Rico
OHSU Knight Cancer Institute
Novartis Pharmaceuticals; Oregon Health and Science University

Completed

Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery

Stage III Soft Tissue Sarcoma AJCC v7 | Stage IV Soft Tissue Sarcoma AJCC v7 | Locally Advanced Leiomyosarcoma | Unresectable Leiomyosarcoma | Myxofibrosarcoma | Metastatic Malignant Peripheral Nerve Sheath Tumor | Metastatic Synovial Sarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Unresectable... and other conditions

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

Lymphoma

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma

Lymphoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma

Lymphoma

United States
ImmunityBio, Inc.

Withdrawn

QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine (TNBC)

Triple Negative Breast Cancer (TNBC)

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors

Ewing Sarcoma of Bone | Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor

United States
National Cancer Institute (NCI)
NRG Oncology

Terminated

Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer AJCC v7 | Stage III Non-Small Cell Lung Cancer AJCC v7 | Stage IIIB Non-Small Cell Lung Cancer AJCC v7

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLC

Completed

Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma

AIDS-related Peripheral/Systemic Lymphoma | AIDS-related Diffuse Large Cell Lymphoma | AIDS-related Diffuse Mixed Cell Lymphoma | AIDS-related Diffuse Small Cleaved Cell Lymphoma | AIDS-related Immunoblastic Large Cell Lymphoma | AIDS-related Lymphoblastic Lymphoma | AIDS-related Small Noncleaved... and other conditions

Zimbabwe, Kenya
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

AIDS-related Peripheral/Systemic Lymphoma | AIDS-related Diffuse Large Cell Lymphoma | AIDS-related Immunoblastic Large Cell Lymphoma | AIDS-related Small Noncleaved Cell Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Splenic Marginal Zone Lymphoma | Waldenström Macroglobulinemia | Testicular Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse... and other conditions

United States

Search clinical trials for: OSI-211 (Liposomal Lurtotecan)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations